Immunogenic cell stress and death in the treatment of cancer

The successful treatment of oncological malignancies which results in long-term disease control or the complete eradication of cancerous cells necessitates the onset of adaptive immune responses targeting tumor-specific antigens. Such desirable anticancer immunity can be triggered via the induction...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Seminars in cell & developmental biology Ročník 156; s. 11 - 21
Hlavní autoři: Pan, Hui, Liu, Peng, Zhao, Liwei, Pan, Yuhong, Mao, Misha, Kroemer, Guido, Kepp, Oliver
Médium: Journal Article
Jazyk:angličtina
Vydáno: England Elsevier Ltd 15.03.2024
Elsevier
Témata:
Antigens, Neoplasm
Antineoplastic Agents - pharmacology
Cell Death
Humans
Life Sciences
Neoplasms - pathology
T-Lymphocytes
ICD
APC
ICI
DAMP
DC
dendritic cells ICD
immune checkpoint inhibitor
immunogenic cell death
antigen presenting cell DAMP
damage associated molecular pattern DC
dendritic cells
damage associated molecular pattern
antigen presenting cell
immunogenic cell death ICI
ISSN:1084-9521, 1096-3634, 1096-3634
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:The successful treatment of oncological malignancies which results in long-term disease control or the complete eradication of cancerous cells necessitates the onset of adaptive immune responses targeting tumor-specific antigens. Such desirable anticancer immunity can be triggered via the induction of immunogenic cell death (ICD) of cancer cells, thus converting malignant cells into an in situ vaccine that elicits T cell mediated adaptive immune responses and establishes durable immunological memory. The exploration of ICD for cancer treatment has been subject to extensive research. However, functional heterogeneity among ICD activating therapies in many cases requires specific co-medications to achieve full-blown efficacy. Here, we described the hallmarks of ICD and classify ICD activators into three distinct functional categories namely, according to their mode of action: (i) ICD inducers, which increase the immunogenicity of malignant cells, (ii) ICD sensitizers, which prime cellular circuitries for ICD induction by conventional cytotoxic agents, and (iii) ICD enhancers, which improve the perception of ICD signals by antigen presenting dendritic cells. Altogether, ICD induction, sensitization and enhancement offer the possibility to convert well-established conventional anticancer therapies into immunotherapeutic approaches that activate T cell-mediated anticancer immunity.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1084-9521
1096-3634
1096-3634
DOI:10.1016/j.semcdb.2023.10.007